The best objective response of target lesions and the incidence of treatment-related hypertension are associated with the survival of patients with metastatic renal cell carcinoma treated with sunitinib: a Japanese retrospective study
Authors:
- Makito MiyakeMakito Miyake
- Masaomi KuwadaMKMasaomi Kuwada
- Shunta HoriSHShunta Hori
- Yosuke MorizawaYMYosuke Morizawa
- Yoshihiro TatsumiYTYoshihiro Tatsumi
- Satoshi AnaiSASatoshi Anai
- Yukinari HosokawaYHYukinari Hosokawa
- Yoshiki HayashiYHYoshiki Hayashi
- Atsushi TomiokaATAtsushi Tomioka
- Takeshi OtaniTOTakeshi Otani
- Kenji OtsukaKOKenji Otsuka
- Yoshinori NakagawaYNYoshinori Nakagawa
Open Access
- 9 February 2016
- journal article
- research article
- Published by Springer Nature in BMC Research Notes
- Vol. 9 (1) , 1-9
Abstract
The aim of this study is to investigate the prognostic relevance of the best objective response of metastatic target lesions during sunitinib treatment in patients with metastatic renal cell carcinoma. Radiographic analysis of the best objective response according to the Response Evaluation Criteria in Solid Tumors was assessed in 50 patients. Clinicopathological characteristics including the Heng risk classification and sunitinib-related adverse reactions were compared among four patient subgroups [complete response or partial response (CR/PR), stable disease (SD), progressive disease (PD), and those without treatment evaluation (NE)]. Kaplan–Meier and Cox proportional regression analyses of progression-free survival and overall survival were performed to identify prognostic variables. The best objective response was CR/PR in 12 (24 %) patients, SD in 22 (44 %), PD in 6 (12 %), and NE in 10 (20 %). The incidence of hypertension and hypothyroidism was associated with a better objective response. Progression-free survival was 15.0, 9.2, 6.8, and 2.2 months in the CR/PR, SD, PD, and NE groups, respectively (P = 0.0004, log-rank test), while the corresponding median overall survival was 59.7, 24.2, 17.1, and 18.1 months, respectively (P = 0.007). Multivariate analysis revealed that hazard ratios for risk of death of the SD, PD, and NE groups were 4.51 (P = 0.06), 7.93 (P = 0.02), and 4.88 (P = 0.04), respectively, as compared to the CR/PR group. Our findings suggested that the best objective response of target lesions was a prognostic marker for both progression-free survival and overall survival in sunitinib treatment. Furthermore, the incidence of sunitinib-induced hypertension was associated with a longer progression-free survival.Keywords
This publication has 28 references indexed in Scilit:
- Progression free survival of first line vascular endothelial growth factor-targeted therapy is an important prognostic parameter in patients with metastatic renal cell carcinomaEuropean Journal of Cancer, 2012
- 5-fluorouracil enhances the antitumor effect of sorafenib and sunitinib in a xenograft model of human renal cell carcinomaOncology Letters, 2012
- Severe clinical toxicities are correlated with survival in patients with advanced renal cell carcinoma treated with sunitinib and sorafenibBritish Journal of Cancer, 2011
- How to select targeted therapy in renal cell cancerAnnals of Oncology, 2010
- Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinibBritish Journal of Cancer, 2010
- Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter StudyJournal of Clinical Oncology, 2009
- Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell CarcinomaJournal of Clinical Oncology, 2009
- Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinomaAnnals of Oncology, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Renal cell cancer: is immunotherapy dead?Annals of Oncology, 2007